Drs. Walther and Georg Birkmayer found that NADH was effective in treating Parkinson's and many other degenerative diseases. Their findings are published. 

Drug companies around the world worked on synthesizing their own. The efforts failed. They were unable to stabilize the NADH. And those that could, were unable to get the body to absorbed the active NADH.

The drug companies could manufacture NADH in liquid, intravenous form. The companies found that the cost of just one NADH treatment was enormous, well beyond what any insurance company would pay for. They also found that NADH doesn't produce immediate results. A patient may have to take months of NADH treatments, lasting weeks or even months before the body responds to an illness. Drug companies knew no insurance company would ever accept such a slow reaction to a medical treatment.

Thousands of patients (that could afford it) continued to travel to Birkmayer Institute for Parkinson's Therapy in Austria. Patients with Parkinson's, Alzheimer's, depression, chronic fatigue syndrome, and the list goes on, they all came. They came spending thousands of dollars for NADH treatments. They came for an NADH treatment that they couldn't get anywhere else.

The other option:
There were other options. Drs. Walther & Georg Birkmayer could make NADH cheaper and easier for people to take. By making NADH a tablet, people could take it without the help of a doctor.

By making NADH cheaper, more people could afford to take NADH. If NADH were cheap enough it could be sold over-the-counter.

The task they set before them was impossible. No big drug companies with all their resources could do it. What makes them think they could? The impossible task these two Drs. would have to perform: create a stable, absorbable (by the body) oral form of NADH that was able to cross the blood brain barrier.

What would they call it? What does the dictionary call NADH? The dictionary calls NADH (èn´â-dê). OK then, that will be its new name: EN-A-DA.

For years, Drs. Walther and Georg Birkmayer continue their research. They put many forms of NADH through many clinical trials. They published their research. Other European Universities read the Birkmayers' work. The other University research medical centers put NADH through clinical trials. They too, published their research. During all this time, everyone working with NADH found it to be a very fragile substance. Sunlight, humidity, even the standard coating on a tablet destroyed the stable NADH. They also found NADH couldn't be stored for more than a couple of days.

It took over ten years, hundreds of disappointments, and countless failures, but Drs. Walter and Georg Birkmayer did it. They were able to create a stable, absorbable, oral form of NADH. They obtained world wide patents to manufacture it. The Birkmayers called it: Co-E1. 

April 1996, Georgetown University Medical Center outside Washington D.C. began their clinical trials of NADH. Georgetown is searching for a treatment of chronic fatigue syndrome (CFS). An incurable, degenerative disease. The preliminary results are excellent.

July 1996, Georgetown University Medical Center began another approved clinical trial. This time Georgetown was testing a treatment for an incurable, degenerative disease called Alzheimer's. The trials are still in progress, and doing very well. 

Make NADH cheaper so more people can take it:
When NADH was first available, each treatment was about 10 times what it costs today.  As Co-E1 becomes less expensive to manufacturer, the savings are passed on to the consumer. As it becomes less expensive, more people will be able to afford it. The Birkmayers brought it to the people as they planned.

The Birkmayers know NADH can be used in the treatment of many degenerative diseases. A dozen Universities around the world are testing it for use in medical treatments. Many research studies have proved NADH is a natural substance, with no known side effects or toxic levels.

It is both Dr. Birkmayer's and our objective is to distribute Co-E1. We know those who need to take NADH has everything to gain and nothing to lose by trying Co-E1.

. . . the footnotes are on the next page